Grounded in proteomic findings, our results showed that HMGB2 expression assessed by IHC detected early signs of tumor progression in grades 2 and 3 astrocytomas, as well as identified GBMs and A4 IDHmut that had better response to the standard chemoradiation with temozolomide. This evidence concerns the gene HMGB2 and astrocytoma (excluding glioblastoma).